Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
Authors:
- Alexander QuaasAQAlexander Quaas
- Carina HeydtCHCarina Heydt
- Dirk WaldschmidtDWDirk Waldschmidt
- Hakan AlakusHAHakan Alakus
- Thomas ZanderTZThomas Zander
- Tobias GoeserTGTobias Goeser
- Philipp KasperPKPhilipp Kasper
- Christiane BrunsChristiane Bruns
- Anna BrunnABAnna Brunn
- Wilfried RothWRWilfried Roth
- Nils HartmannNHNils Hartmann
- Anne BunckABAnne Bunck
Open Access
- 4 February 2019
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-6
Abstract
Carcinomas of the small bowel are rare tumors usually with dismal prognosis. Most recently, some potentially treatable molecular alterations were described. We emphasize the growing evidence of individualized treatment options in small bowel carcinoma. We performed a DNA- based multi-gene panel using ultra-deep sequencing analysis (including 14 genes with up to 452 amplicons in total; KRAS, NRAS, HRAS, BRAF, DDR2, ERBB2, KEAP1, NFE2L2, PIK3CA, PTEN, RHOA, BRCA1, BRCA2 and TP53) as well as an RNA-based gene fusion panel including ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 on eleven formalin fixed and paraffin embedded small bowel carcinomas. Additionally, mismatch-repair-deficiency was analyzed by checking the microsatellite status using the five different mononucleotide markers BAT25, BAT26, NR-21, NR-22 and NR-27 and loss of mismatch repair proteins using four different markers (MLH1, MSH6, MSH2, PMS2). In five out of eleven small bowel carcinomas we found potentially treatable genetic alterations. Three patients demonstrated pathogenic (class 5) BRCA1 or BRCA2 mutations – one germline-related in a mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN). Two additional patients revealed an activating ERBB2 mutation or PIK3CA mutation. Furthermore two tumors were highly microsatellite-instable (MSI-high), in one case associated to Lynch-syndrome. We did not find any gene fusions. Our results underscore, in particular, the relevance of potentially treatable molecular alterations (like ERBB2, BRCA and MSI) in small bowel carcinomas. Further studies are needed to proof the efficacy of these targeted therapies in small bowel carcinomas.Keywords
This publication has 31 references indexed in Scilit:
- Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995–2002European Journal of Cancer, 2012
- A Multicenter Study to Validate the Reproducibility of MSI Testing With a Panel of 5 Quasimonomorphic Mononucleotide RepeatsDiagnostic Molecular Pathology, 2010
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian CancerJournal of Clinical Oncology, 2010
- Worldwide Variations in Colorectal CancerCA: A Cancer Journal for Clinicians, 2009
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Cancer risks among BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 2007
- Incidence and Management of Primary Malignant Small Bowel Cancers: A Well-defined French Population StudyAmerican Journal of Gastroenterology, 2006
- Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestineCancer, 2003
- Genome maintenance mechanisms for preventing cancerNature, 2001